Instrument Inactif

Autres langues Oasmia Pharmaceutical AB NORDIC GROWTH MARKET

Actions

OASM

SE0000722365

Produits pharmaceutiques

Autres langues

13/08	Vivesto: Largely a non-event, key readouts ahead – Q2 review
13/08	Vivesto AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
01/07	Vivesto: Cat study enrolment completed, results expected in Q4
01/07	Vivesto completes recruitment in Paccal Vet study in cats and determines maximum tolerated dose
01/07	Vivesto Completes Recruitment in Paccal Vet Dose-Finding Study in Cats and Determines Maximum Tolerated Dose
26/06	Vivesto: Paccal Vet top-line results expected in Q3
26/06	Vivesto completes recruitment in Paccal Vet dog pilot study – topline results expected Q3 2026
26/06	Vivesto Completes Recruitment in Paccal Vet Dog Pilot Study
16/06	Vivesto AB Reports Positive Results From Intravenous Cantrixil Pharmacokinetic And Toxicology Study
16/06	Vivesto: Positive data for Cantrixil
16/06	Vivesto reports positive results from i.v. Cantrixil PK/toxicology study
05/06	Sweden's Vivesto Names New Finance Chief
05/06	Vivesto appoints Björn Svanström as CFO
05/06	Vivesto AB Announces Chief Financial Officer Changes
29/05	New number of shares and votes in Vivesto
26/05	Vivesto: Minor model adjustments
13/05	Vivesto sets record date for reverse share split as May 21, 2026
13/05	Vivesto announces timetable for reverse share split
07/05	Vivesto: Purring along – Q1 review
07/05	Vivesto : Minutes AGM 2026 – May 6, 2026 (minutes agm 2026 may 6 2026)
07/05	Report from Annual General Meeting in Vivesto AB
07/05	Vivesto Q1 operating result of SEK -6.8 mln
07/05	Vivesto AB Reports Earnings Results for the First Quarter Ended March 31, 2026
14/04	Vivesto : Remuneration report 2025 (remuneration report 2025 vivesto ab)
13/04	Vivesto : Auditor’s report – remuneration to group executive management Vivesto 2025 (auditors report remuneration to group executive management vivesto 2025)